Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.25
+3.5%
$0.27
$0.20
$1.48
$66.53M2.181.65 million shs459,962 shs
Agenus Inc. stock logo
AGEN
Agenus
$5.93
+7.6%
$4.19
$1.38
$18.74
$162.60M1.51687,334 shs1.27 million shs
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
$23.00
$23.01
$9.02
$23.35
$787.66M1.59955,800 shsN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$35.35
-0.6%
$32.40
$6.76
$46.98
$3.36B0.331.29 million shs481,993 shs
Vericel Corporation stock logo
VCEL
Vericel
$41.79
+0.8%
$41.68
$37.39
$63.00
$2.10B1.32417,678 shs161,609 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
0.00%+2.45%-11.31%-2.11%-79.43%
Agenus Inc. stock logo
AGEN
Agenus
0.00%+24.58%-0.34%+222.28%-60.81%
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
0.00%0.00%0.00%0.00%0.00%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.00%-1.28%+3.27%+35.75%+356.72%
Vericel Corporation stock logo
VCEL
Vericel
0.00%+0.13%-3.50%+4.72%-10.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.1624 of 5 stars
3.15.00.00.01.50.80.0
Agenus Inc. stock logo
AGEN
Agenus
4.2673 of 5 stars
3.24.00.04.62.01.70.6
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.3351 of 5 stars
2.60.00.04.41.13.30.6
Vericel Corporation stock logo
VCEL
Vericel
2.8356 of 5 stars
3.51.00.00.02.90.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35438.51% Upside
Agenus Inc. stock logo
AGEN
Agenus
2.33
Hold$14.00136.09% Upside
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
0.00
N/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.14
Buy$42.6720.70% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1446.33% Upside

Current Analyst Ratings Breakdown

Latest SRRK, PRVL, AGEN, VCEL, and ADAP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/18/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$25.00
6/3/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
5/14/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.37N/AN/A$0.05 per share5.02
Agenus Inc. stock logo
AGEN
Agenus
$103.46M1.57N/AN/A($13.06) per share-0.45
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/A$4.85 per shareN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M101.13N/AN/A$3.94 per share8.97
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.87$0.31 per share133.57$5.92 per share7.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,393.3094.97N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest SRRK, PRVL, AGEN, VCEL, and ADAP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/12/2025Q1 2025
Agenus Inc. stock logo
AGEN
Agenus
-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.11
0.11
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/A
7.56
7.56
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.16
10.25
10.25
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
86.80%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
12.44%
Agenus Inc. stock logo
AGEN
Agenus
5.50%
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
57.20%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million232.08 millionOptionable
Agenus Inc. stock logo
AGEN
Agenus
44027.42 million25.91 millionOptionable
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
6634.25 millionN/ANot Optionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14094.95 million82.32 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million46.72 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.25 +0.01 (+3.55%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$0.25 0.00 (0.00%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Agenus stock logo

Agenus NASDAQ:AGEN

$5.93 +0.42 (+7.62%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$5.91 -0.02 (-0.40%)
As of 05:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Prevail Therapeutics stock logo

Prevail Therapeutics NASDAQ:PRVL

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$35.35 -0.20 (-0.56%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$35.19 -0.16 (-0.45%)
As of 05:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Vericel stock logo

Vericel NASDAQ:VCEL

$41.78 +0.33 (+0.78%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$41.78 0.00 (0.00%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.